
BOSTON, USA – December 12, 2026 – The global medical community remains on an urgent quest for effective treatments for Alzheimer’s disease, a devastating neurodegenerative condition. In a highly anticipated presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, Priavoid GmbH unveiled Phase II efficacy data for its oral Alzheimer’s drug, PRI-002. While the study, named PRImus-AD, did not achieve statistical significance on its primary efficacy endpoint at the 48-week mark, a closer examination of exploratory analyses and the drug’s robust safety profile has sparked cautious optimism, suggesting a potential for slowing cognitive and functional decline that warrants further, extensive investigation.
n
The findings underscore the complex nature of Alzheimer’s drug development, where initial statistical hurdles can sometimes obscure encouraging clinical trends. For patients and caregivers yearning for more accessible and tolerable treatment options, an oral therapy like PRI-002, demonstrating a favorable safety profile and hints of efficacy, represents a beacon of hope in a landscape dominated by intravenous infusions and limited disease-modifying options.
n
The PRImus-AD Study: Design and Objectives
n
The PRImus-AD study (NCT06182085) was designed as a crucial Phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of PRI-002 in patients diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease. This patient population is particularly critical, as interventions at these early stages are increasingly believed to offer the best chance of slowing disease progression and preserving cognitive function and independence.
n
A total of 304 patients were enrolled and randomly assigned to one of three treatment arms: a daily oral dose of 300mg PRI-002, 600mg PRI-002, or a placebo. The oral administration route itself is a significant advantage, promising greater convenience and potentially higher patient adherence compared to existing intravenous therapies. The study’s primary objective was to assess the safety and tolerability of PRI-002 over the treatment period, a fundamental prerequisite for any new drug entering the therapeutic arena. Secondary endpoints focused on various measures of disease progression, including cognitive function, daily living activities, and global dementia severity, evaluated at 48 weeks and extended to 72 weeks for exploratory analysis.
n
The choice of endpoints reflects the multifaceted impact of Alzheimer’s disease. The Clinical Dementia Rating – Sum of Boxes (CDR-SB) is a widely used and comprehensive measure that assesses cognitive and functional performance across six domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. It provides a global snapshot of disease severity and progression. The Alzheimer’s Disease Assessment Scale – Cognitive Subscale, 13-item version (ADAS-Cog13), specifically targets cognitive functions such as memory, language, and praxis, offering a more granular view of intellectual decline. Lastly, the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) scale evaluates a patient’s ability to perform everyday tasks, a crucial indicator of functional independence and overall quality of life. The inclusion of these diverse measures aimed to capture a holistic picture of the drug’s potential impact.
n
Efficacy Data: Nuances and Interpretations
n
The efficacy data presented at CTAD 2026 revealed a complex picture, characteristic of early-stage trials in neurodegenerative diseases. While the primary efficacy analysis did not meet the rigorous statistical threshold at 48 weeks, deeper dives into secondary and exploratory endpoints suggest underlying benefits that Priavoid believes warrant continued development.
n
Primary Endpoint: Clinical Dementia Rating – Sum of Boxes (CDR-SB)
n
The most notable point from the Phase II PRImus-AD study was that PRI-002 failed to achieve statistical significance on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) at the primary 48-week assessment. This outcome, while a setback for a primary endpoint, is not uncommon in Phase II Alzheimer’s trials, where patient heterogeneity, subtle effects, and the relatively short duration can make robust statistical significance challenging. The CDR-SB is a high-bar measure, requiring a substantial and consistent clinical effect to demonstrate statistical superiority over placebo.
n
However, the exploratory analysis at week 72 offered a glimmer of hope. In the modified intention-to-treat (mITT) population, PRI-002 was associated with a 12% slowing of decline on the CDR-SB compared to placebo. The per-protocol population, which includes only those patients who completed the study as planned without major deviations, showed an 8% slowing. While these percentages are not statistically significant, they suggest a consistent, albeit modest, trend towards reduced clinical progression. For a disease like Alzheimer’s, where even a small delay in decline can significantly improve patients’ quality of life and reduce caregiver burden, such signals are closely scrutinized by researchers. The difference between mITT and per-protocol populations often provides insight into the drug’s efficacy under ideal versus real-world conditions, and the consistent directional trend across both groups is encouraging.
n
Cognitive Decline: Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13)
n
More compelling signals emerged from the analysis of the ADAS-Cog13, which focuses specifically on cognitive performance. At week 48, treatment with PRI-002 showed a 19% slowing of cognitive decline in the mITT population compared to placebo, with an even more pronounced 23.3% slowing observed in the per-protocol population. These figures, while not reaching statistical significance independently, hinted at a positive impact on core cognitive functions.
n
The exploratory week 72 data further strengthened this observation, revealing an acceleration of the beneficial trend. At this later time point, the mITT population demonstrated a 26.7% slowing of cognitive decline, while the per-protocol population exhibited an impressive 35.9% slowing. Priavoid highlighted these findings as an "encouraging signal for further investigation." The increasing magnitude of the effect over time is particularly noteworthy in neurodegenerative diseases, where drug effects may accumulate or become more apparent with longer exposure. This suggests that PRI-002 might be exerting a sustained, disease-modifying effect that becomes more evident beyond the initial 48-week period.
n
Functional Independence: Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL)
n
The ADCS-ADL endpoint, which measures a patient’s ability to perform routine daily activities, is arguably one of the most clinically meaningful outcomes for patients and their families. At week 48, PRI-002 showed a 7.5% difference favoring treatment over placebo in the mITT population, indicating a potential benefit in preserving daily functioning. This difference was even more substantial in the per-protocol population, reaching 16.9%.
n
However, the week 72 data presented a more complex picture. In the mITT population, the difference favoring PRI-002 narrowed to just 1%, suggesting a diminished effect or increased variability. Conversely, in the per-protocol population, the difference surged to 30.4%, indicating a significantly greater preservation of daily living activities. This divergence between the mITT and per-protocol populations at week 72 warrants careful consideration. It could be influenced by factors such as patient attrition in the mITT group, variations in compliance, or the possibility that the drug’s benefits are more robust in a highly compliant patient subset. Despite the variability, the strong signal in the per-protocol population at week 72 suggests a "potential benefit in preserving patients’ ability to perform everyday activities," a critical aspect of maintaining independence and quality of life for Alzheimer’s patients.
n
Safety and Tolerability: A Foundation for Progress
n
While efficacy data can be challenging to interpret in early-stage trials, the safety and tolerability profile of a new drug are paramount. On this front, PRI-002 delivered unequivocal positive news, successfully meeting its primary safety endpoint. The drug demonstrated a favorable safety and tolerability profile, which is a significant achievement for any investigational therapy, especially one targeting a chronic disease that requires long-term treatment.
n
Adverse events (AEs) commonly associated with amyloid-targeting drugs, known as Amyloid-Related Imaging Abnormalities (ARIA), were reported at manageable levels. ARIA-E (oedema, or swelling in the brain) was observed in 2% of patients receiving 300mg PRI-002, 0% in the 600mg group, and 1% in the placebo group. ARIA-H (haemorrhage, or microbleeds in the brain) was reported in 8% of patients on 300mg, 11.7% on 600mg, and 5% in the placebo group. These rates are generally comparable to, or in some cases lower than, those seen with currently approved anti-amyloid antibody therapies, which are often a concern for clinicians and patients. The absence of ARIA-E in the higher dose group is particularly interesting and may suggest a dose-dependent or idiosyncratic response.
n
Beyond ARIA, the most commonly reported adverse events were headache, nausea, and dizziness. These are generally mild to moderate in severity and are often manageable with standard symptomatic treatment, further supporting the drug’s favorable tolerability. The oral administration of PRI-002 also presents a distinct advantage in terms of safety and patient convenience. Unlike intravenous infusions that require regular clinic visits and can be associated with infusion-related reactions, an oral pill can be taken at home, potentially reducing the burden on both patients and healthcare systems, and improving overall adherence to treatment. This ease of administration, coupled with a benign safety profile, significantly enhances its appeal as a potential long-term treatment option.

n
Official Responses and Forward Outlook
n
The topline data were presented during the highly anticipated 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, USA, a leading forum for showcasing cutting-edge research in Alzheimer’s. While these initial results provide crucial insights, the full dataset, which will include additional safety, clinical efficacy, and biomarker analyses, is slated for unveiling at scientific conferences in 2027. This forthcoming data, particularly the biomarker findings, will be instrumental in further elucidating PRI-002’s mechanism of action and its biological effects on the disease pathology.
n
Priavoid’s Stance
n
Professor Oliver Peters, Chief Medical Officer (CMO) of Priavoid, articulated the company’s perspective on the Phase II results with a tone of cautious optimism and determination. "PRI-002 has demonstrated a favourable safety and tolerability profile, combined with a convenient oral treatment regimen," stated Professor Peters. He underscored the potential impact of such a therapy on the lives of those affected by Alzheimer’s, noting, "For people living with Alzheimer’s disease, a treatment that could slow cognitive and functional decline while fitting into their daily lives would contribute to quality of life."
n
Despite the lack of statistical significance on the primary endpoint, Priavoid remains committed to advancing the drug’s development. Professor Peters explained this decision by citing the "encouraging clinical signals, favourable safety profile and preliminary biomarker findings." This implies that even without the full biomarker data, initial indications are positive enough to reinforce their belief in PRI-002. The company positions PRI-002 as a "potentially disease-modifying therapy," a significant claim in a field where such treatments are scarce. The decision to continue development reflects a strategic approach often seen in neurodegenerative research, where even subtle or exploratory signals, especially when coupled with excellent safety, can warrant progression to larger, longer Phase III trials. These trials are designed to definitively establish efficacy and statistical significance over extended periods.
n
Expert Commentary
n
The scientific community generally acknowledges the immense challenges inherent in developing treatments for Alzheimer’s disease. The brain’s complexity, the slow progression of the disease, and the heterogeneity among patients make clear-cut results difficult to achieve, especially in Phase II studies. Independent experts, while acknowledging the statistical miss on the primary endpoint, often emphasize the importance of looking beyond raw p-values in early-stage drug development for neurodegenerative conditions. The consistent signals observed across multiple secondary cognitive and functional endpoints, coupled with a highly favorable safety and tolerability profile, are often considered sufficient justification for further, larger-scale investigation. The convenience of an oral formulation further enhances its potential utility, addressing a significant unmet need for accessible treatments. The anticipation for the full dataset, particularly biomarker analyses, is high, as these could provide objective evidence of biological activity, thereby strengthening the case for PRI-002.
n
Broader Landscape of Alzheimer’s Treatment
n
The context in which PRI-002’s results are presented is one of both immense challenge and burgeoning hope. For decades, Alzheimer’s treatment was limited to symptomatic therapies that offered modest, temporary relief without altering the disease’s underlying progression. However, recent breakthroughs have ushered in a new era of disease-modifying treatments, though significant unmet needs persist.
Current Disease-Modifying Therapies
Currently, only a handful of disease-modifying options are available for Alzheimer’s disease patients, primarily targeting amyloid-beta pathology, a hallmark of the disease. These include Eli Lilly’s Kisunla (donanemab) and Biogen and Eisai’s Leqembi (lecanemab). Both are monoclonal antibodies administered via intravenous infusion, designed to clear amyloid plaques from the brain. While they have demonstrated the ability to slow cognitive decline, they come with caveats, including the potential for side effects like ARIA (Amyloid-Related Imaging Abnormalities) and the logistical burden of regular infusions. These limitations highlight the urgent need for more diverse, safer, and more convenient treatment modalities, particularly oral options.
Emerging Late-Stage Assets
The pipeline for Alzheimer’s therapies is robust, with several other promising late-stage assets vying for approval, signaling a dynamic period of innovation. Also at the CTAD conference, AriBio presented encouraging Phase III data for its oral drug, AR1001. This therapy met its primary endpoint in a prespecified monotherapy population, showing a 0.44-point difference between AR1001 and placebo in their CDR-SB scores, equating to a significant 31% slowing of clinical decline. The success of AR1001, another oral candidate, further validates the potential for non-infusion-based treatments and underscores the competitive yet collaborative spirit in the field.
Eli Lilly is also actively developing another therapy, remternetug, which shares the same target as its approved therapy, donanemab, but may offer different characteristics or administration routes. Meanwhile, Roche is progressing with Phase III trials for trontinemab, another anti-amyloid drug. Trontinemab incorporates advanced technology designed to enhance its penetration of the blood-brain barrier, aiming for improved efficacy and potentially reduced dosing. These diverse approaches, targeting different mechanisms or improving delivery, collectively point towards a future with a broader arsenal against Alzheimer’s disease. The potential for PRI-002, with its distinct mechanism (which the article implies is not strictly anti-amyloid in the same manner as the antibodies, given the lower ARIA rates), and oral convenience, to join these ranks is a significant driver for its continued development.
The Unmet Need
Despite these advancements, the unmet medical need in Alzheimer’s disease remains immense. Millions of individuals worldwide suffer from the debilitating effects of this progressive condition, which strips away memory, cognitive abilities, and independence. The demand for therapies that can effectively slow, halt, or even reverse the disease’s progression is staggering. Oral treatments, in particular, offer a pathway to broader accessibility, easier integration into daily life, and potentially better long-term adherence, which are crucial factors for a chronic disease requiring continuous management. The current landscape, while improving, still leaves many patients without viable, accessible options, underscoring the importance of continued research into drugs like PRI-002.
Market Outlook and Future Prospects
The financial and societal impact of Alzheimer’s disease is enormous, driving significant investment and intense competition in the pharmaceutical sector. The market for Alzheimer’s disease treatments is poised for substantial growth in the coming years, fueled by an aging global population, increasing diagnosis rates, and the introduction of novel therapies.
Alzheimer’s Disease Market Growth
According to analysts at GlobalData, the Alzheimer’s disease market across the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China) is projected to experience robust expansion. Forecasts indicate a growth from $2.4 billion in 2023 to an estimated $14.7 billion by 2033, representing an impressive Compound Annual Growth Rate (CAGR) of 20%. This explosive growth is a testament to the urgent demand for effective treatments and the anticipated commercial success of disease-modifying drugs, even those offering incremental benefits. The increasing understanding of the disease, coupled with the potential for earlier diagnosis and intervention, will further contribute to this market expansion. Companies that can bring safe, effective, and convenient therapies to market stand to capture significant shares of this burgeoning sector.
The Road Ahead for PRI-002
For Priavoid and PRI-002, the path forward is clear but challenging. The encouraging signals from the Phase II PRImus-AD study, particularly in the exploratory week 72 analyses of ADAS-Cog13 and ADCS-ADL, combined with an exemplary safety profile and the convenience of an oral formulation, provide a strong rationale for advancing to Phase III trials. These larger, pivotal studies will be critical to definitively establish PRI-002’s efficacy, statistical significance, and long-term safety. Phase III trials will involve a significantly larger patient cohort, often spanning multiple countries, and will typically run for longer durations to capture more robust data on disease progression.
The upcoming release of the full dataset in 2027, especially the biomarker analyses, will be crucial. Biomarkers, such as changes in amyloid and tau levels in cerebrospinal fluid or via PET imaging, could provide objective evidence of PRI-002’s biological activity and mechanism of action. Positive biomarker data would lend considerable weight to the observed clinical signals, bolstering confidence in its potential as a disease-modifying therapy and supporting its progression through the regulatory pipeline. If successful, PRI-002 could offer a valuable, orally administered option in a market hungry for innovation, providing patients with a much-needed alternative to current therapies.
Conclusion
The Phase II results for Priavoid’s oral Alzheimer’s drug, PRI-002, present a nuanced yet ultimately hopeful outlook. While the drug did not achieve statistical significance on its primary efficacy endpoint at 48 weeks, the consistent and increasingly positive trends observed in exploratory analyses of cognitive and functional measures at 72 weeks, coupled with an excellent safety and tolerability profile, provide compelling reasons for further investigation. The convenience of an oral regimen further enhances its appeal in a field dominated by infused therapies.
As the Alzheimer’s disease market continues its rapid expansion, driven by an aging global population and the urgent demand for effective treatments, therapies like PRI-002, even with their initial statistical hurdles, represent critical steps forward. Priavoid’s commitment to continue developing PRI-002, based on these "encouraging clinical signals," positions it as a promising candidate in the growing pipeline of potential disease-modifying treatments. The scientific and patient communities eagerly await the full dataset and the next stages of development, hopeful that PRI-002 can ultimately offer a meaningful contribution to the fight against this devastating disease.